

SENATE BILL NO. 616

October 22, 2025, Introduced by Senator SANTANA and referred to Committee on Civil Rights, Judiciary, and Public Safety.

A bill to amend 2022 PA 85, entitled
"Opioid liability litigation act,"
by amending sections 2 and 3 (MCL 691.1672 and 691.1673), as
amended by 2023 PA 228.

THE PEOPLE OF THE STATE OF MICHIGAN ENACT:

- 1 Sec. 2. As used in this act:
- 2 (a) "Allergan settlement" means the master settlement
- 3 agreement arising out of the MDL and entered into by this state
- 4 with Allergan Pharmaceuticals.

1 (b) "Alvogen settlement" means the master settlement agreement
2 arising out of the MDL and entered into by this state with Alvogen,
3 Incorporated.

4 (c) "Amneal settlement" means the master settlement agreement
5 arising out of the MDL and entered into by this state with Amneal
6 Pharmaceuticals, LLC.

7 (d) "Apotex settlement" means the master settlement agreement
8 arising out of the MDL and entered into by this state with Apotex
9 Corporation.

10 (e) ~~(b)~~ "CVS settlement" means the master settlement agreement
11 arising out of the MDL and entered into by this state with CVS
12 Pharmacy.

13 (f) ~~(e)~~ "Distributor settlement" means the master settlement
14 agreement arising out of the MDL and entered into by this state
15 with AmerisourceBergen Corporation, Cardinal Health, Inc., and
16 McKesson Corporation.

17 (g) "Hikma settlement" means the master settlement agreement
18 arising out of the MDL and entered into by this state with Hikma
19 Pharmaceuticals USA, Incorporated.

20 (h) "Indivior settlement" means the master settlement
21 agreement arising out of the MDL and entered into by this state
22 with Indivior, Incorporated.

23 (i) ~~(d)~~ "Janssen settlement" means the master settlement
24 agreement arising out of the MDL and entered into by this state
25 with Janssen Pharmaceuticals, Inc.

26 (j) "Kroger settlement" means the master settlement agreement
27 arising out of the MDL and entered into by this state with the
28 Kroger Co.

29 (k) ~~(e)~~ "MDL" means *In re Nat'l Prescription Opiate*

1 *Litigation*, multidistrict litigation consolidated in the United
2 States District Court for the Northern District of Ohio, Case No.
3 1:17-MD-2804.

4 **(l) "Mylan settlement" means the master settlement agreement**
5 **arising out of the MDL and entered into by this state with Viatris,**
6 **Inc.**

7 **(m) ~~(f)~~**"Political subdivision" means a public body corporate
8 in this state, an agency of a public body corporate in this state,
9 a nonincorporated body in this state of whatever nature, or an
10 agency of a nonincorporated body in this state. Political
11 subdivision includes a county, city, village, township, school
12 district, or special district or authority of this state. Political
13 subdivision does not include this state.

14 **(n) "Purdue settlement" means the Governmental Entity and**
15 **Shareholder Direct Settlement Agreement in the bankruptcy action *In***
16 ***re Purdue Pharma LP et al*, Case No. 19-23649 (SHL) (Bankr SDNY), to**
17 **which this state is a party.**

18 **(o) "Sun settlement" means the master settlement agreement**
19 **arising out of the MDL and entered into by this state with Sun**
20 **Pharmaceuticals, Incorporated.**

21 **(p) ~~(g)~~**"Teva settlement" means the master settlement
22 agreement arising out of the MDL and entered into by this state
23 with Teva Pharmaceuticals.

24 **(q) ~~(h)~~**"Walgreens national settlement" means the master
25 settlement agreement arising out of the MDL and entered into by
26 this state with Walgreens Pharmacy.

27 **(r) ~~(i)~~**"Walmart settlement" means the master settlement
28 agreement arising out of the MDL and entered into by this state
29 with Walmart.

1 **(s) "Zydus settlement" means the master settlement agreement**
2 **arising out of the MDL and entered into by this state with Zydus**
3 **Pharmaceuticals (USA), Inc.**

4 Sec. 3. A political subdivision of this state shall not
5 commence or maintain an action as follows:

6 (a) After January 1, 2021, an action related to the released
7 claims as defined in the distributor settlement against the
8 released entities as defined in the distributor settlement.

9 (b) After January 1, 2021, an action related to the released
10 claims as defined in the Janssen settlement against the released
11 entities as defined in the Janssen settlement.

12 (c) After January 1, 2022, an action related to the released
13 claims as defined in the Allergan settlement against the released
14 entities as defined in the Allergan settlement.

15 (d) After January 1, 2022, an action related to the released
16 claims as defined in the CVS settlement against the released
17 entities as defined in the CVS settlement.

18 (e) After January 1, 2022, an action related to the released
19 claims as defined in the Teva settlement against the released
20 entities as defined in the Teva settlement.

21 (f) After January 1, 2022, an action related to the released
22 claims as defined in the Walgreens national settlement against the
23 released entities as defined in the Walgreens national settlement.

24 (g) After January 1, 2022, an action related to the released
25 claims as defined in the Walmart settlement against the released
26 entities as defined in the Walmart settlement.

27 **(h) After January 1, 2024, an action related to the released**
28 **claims as defined in the Kroger settlement against the released**
29 **entities as defined in the Kroger settlement.**

1 (i) After January 1, 2025, an action related to the
2 Shareholder Released Claims as defined in the Purdue settlement
3 against the Shareholder Released Persons as defined in the Purdue
4 settlement.

5 (j) After January 1, 2025, an action related to the released
6 claims as defined in the Alvogen settlement against the released
7 entities as defined in the Alvogen settlement.

8 (k) After January 1, 2025, an action related to the released
9 claims as defined in the Amneal settlement against the released
10 entities as defined in the Amneal settlement.

11 (l) After January 1, 2025, an action related to the released
12 claims as defined in the Apotex settlement against the released
13 entities as defined in the Apotex settlement.

14 (m) After January 1, 2025, an action related to the released
15 claims as defined in the Hikma settlement against the released
16 entities as defined in the Hikma settlement.

17 (n) After January 1, 2025, an action related to the released
18 claims as defined in the Indivior settlement against the released
19 entities as defined in the Indivior settlement.

20 (o) After January 1, 2025, an action related to the released
21 claims as defined in the Mylan settlement against the released
22 entities as defined in the Mylan settlement.

23 (p) After January 1, 2025, an action related to the released
24 claims as defined in the Sun settlement against the released
25 entities as defined in the Sun settlement.

26 (q) After January 1, 2025, an action related to the released
27 claims as defined in the Zydus settlement against the released
28 entities as defined in the Zydus settlement.